GlassScriptPhysician profile
Arthur L Hughes
NPI 1114037991
$6,253.74
in general payments reported to CMS, 2019-2025
34 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $201 · 2021: $721 · 2022: $755 · 2023: $1,544 · 2024: $1,016 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,603 · Education: $35.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,602.62 |
| Education | $35.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $915.34 | 2022-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $871.85 | 2019-2024 | Rytary, Lyvispah |
| Sk Life Science, INC. | $525.59 | 2022-2025 | |
| Ucb, INC. | $524.45 | 2019-2025 | Rystiggo, Zilbrysq |
| Mdd US Operations, LLC | $434.35 | 2021-2025 | Gocovri, Gocovri |
| Alexion Pharmaceuticals, INC. | $346.13 | 2019-2024 | Ultomiris, Soliris |
| Genzyme Corporation | $345.33 | 2019-2025 | |
| Abbvie INC. | $325.98 | 2022-2025 | |
| Lilly USA, LLC | $297.66 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Biogen, INC. | $282.86 | 2019-2025 | Vumerity, Leqembi |
| Novartis Pharmaceuticals Corporation | $228.11 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $147.03 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $120.82 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $109.71 | 2021-2023 | Spritam |
| Pfizer INC. | $96.36 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $86.53 | 2023 | Adlarity |
| Acadia Pharmaceuticals INC | $83.23 | 2024-2025 | Nuplazid |
| Argenx US, INC. | $78.89 | 2023 | Vyvgart |
| Emd Serono, INC. | $56.69 | 2019 | |
| Nevro Corp. | $53.37 | 2019 | |
| Sunovion Pharmaceuticals INC. | $45.97 | 2019 | |
| Acorda Therapeutics, INC | $33.00 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Adamas Pharmaceuticals, INC. | $28.00 | 2021 | |
| Eisai INC. | $27.33 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.92 | 2022 | |
| Boston Scientific Corporation | $25.02 | 2019 | |
| Amgen INC. | $18.33 | 2025 | Uplizna |
| Celgene Corporation | $18.24 | 2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $17.36 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $14.50 | 2021 | |
| Kyowa Kirin, INC. | $14.25 | 2024 | Nourianz |
| Lundbeck LLC | $12.50 | 2019 | |
| Greenwich Biosciences, INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.